Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 55.00 | |
10 mg | In stock | $ 97.00 | |
25 mg | In stock | $ 198.00 | |
50 mg | In stock | $ 372.00 | |
100 mg | In stock | $ 553.00 | |
200 mg | In stock | $ 792.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 68.00 |
Description | Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations(KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively). BDTX-189 exhibits anticancer activity. |
Targets&IC50 | EGFR:0.2 nM(KD), BLK:13 nM(KD), RIPK2:1.2 nM(KD), HER2:0.76 nM(KD) |
In vivo | BDTX-189 (0-100 mg/kg;?p.o.;?daily for 15 dyas) shows dose-dependent tumor growth inhibition and regression in in athymic nude mice bearing HER2 S310F Ba/F3 allograft tumors.?BDTX-189 (1-50 mg/kg.p.o.;?daily for 15 days) shows dose-dependent tumor growth inhibition and regression in athymic nude mice bearing CUTO-14 PDX tumors that express the EGFR mutation EGFR ASV |
Synonyms | BDTX-189 |
Molecular Weight | 561.03 |
Formula | C29H29ClN6O4 |
CAS No. | 2414572-47-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 41.67 mg/mL (74.27 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tuxobertinib 2414572-47-5 Angiogenesis Apoptosis JAK/STAT signaling NF-Κb Tyrosine Kinase/Adaptors HER EGFR BTK RIP kinase inhibit BDTX189 ErbB-1 mutants Epidermal growth factor receptor BDTX-189 nude allosteric Ba/F3 BDTX 189 HER1 oncogene athymic oral mice insertion Inhibitor inhibitor